Affibody molecules as engineered protein drugs

Affibody molecules can be used as tools for molecular recognition in diagnostic and therapeutic applications. There are several preclinical studies reported on diagnostic and therapeutic use of this molecular class of alternative scaffolds, and early clinical evidence is now beginning to accumulate...

Descripción completa

Detalles Bibliográficos
Autores principales: Frejd, Fredrik Y, Kim, Kyu-Tae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5382565/
https://www.ncbi.nlm.nih.gov/pubmed/28336959
http://dx.doi.org/10.1038/emm.2017.35
_version_ 1782520126585700352
author Frejd, Fredrik Y
Kim, Kyu-Tae
author_facet Frejd, Fredrik Y
Kim, Kyu-Tae
author_sort Frejd, Fredrik Y
collection PubMed
description Affibody molecules can be used as tools for molecular recognition in diagnostic and therapeutic applications. There are several preclinical studies reported on diagnostic and therapeutic use of this molecular class of alternative scaffolds, and early clinical evidence is now beginning to accumulate that suggests the Affibody molecules to be efficacious and safe in man. The small size and ease of engineering make Affibody molecules suitable for use in multispecific constructs where AffiMabs is one such that offers the option to potentiate antibodies for use in complex disease.
format Online
Article
Text
id pubmed-5382565
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-53825652017-04-07 Affibody molecules as engineered protein drugs Frejd, Fredrik Y Kim, Kyu-Tae Exp Mol Med Review Affibody molecules can be used as tools for molecular recognition in diagnostic and therapeutic applications. There are several preclinical studies reported on diagnostic and therapeutic use of this molecular class of alternative scaffolds, and early clinical evidence is now beginning to accumulate that suggests the Affibody molecules to be efficacious and safe in man. The small size and ease of engineering make Affibody molecules suitable for use in multispecific constructs where AffiMabs is one such that offers the option to potentiate antibodies for use in complex disease. Nature Publishing Group 2017-03 2017-03-24 /pmc/articles/PMC5382565/ /pubmed/28336959 http://dx.doi.org/10.1038/emm.2017.35 Text en Copyright © 2017 The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Review
Frejd, Fredrik Y
Kim, Kyu-Tae
Affibody molecules as engineered protein drugs
title Affibody molecules as engineered protein drugs
title_full Affibody molecules as engineered protein drugs
title_fullStr Affibody molecules as engineered protein drugs
title_full_unstemmed Affibody molecules as engineered protein drugs
title_short Affibody molecules as engineered protein drugs
title_sort affibody molecules as engineered protein drugs
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5382565/
https://www.ncbi.nlm.nih.gov/pubmed/28336959
http://dx.doi.org/10.1038/emm.2017.35
work_keys_str_mv AT frejdfredriky affibodymoleculesasengineeredproteindrugs
AT kimkyutae affibodymoleculesasengineeredproteindrugs

Ejemplares similares